NCT03129126View on ClinicalTrials.gov

The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

August 21, 2023

Study Completion Date

September 29, 2023

Conditions
Hemorrhagic Cystitis
Interventions
DRUG

LP-10

Intravesical tacrolimus

Trial Locations (9)

12603

Premier Medical Group, Poughkeepsie

15212

Allegheny Health Network Research Institute, Pittsburgh

19140

Temple University, Philadelphia

30322

Emory University, Atlanta

37232

Vanderbilt University Medical Center, Nashville

48084

Michigan Institute of Urology, Troy

77030

Baylor College of Medicine, Houston

85724

University of Arizona, Tucson

94122

University of California San Francisco, San Francisco

Sponsors
All Listed Sponsors
lead

Lipella Pharmaceuticals, Inc.

INDUSTRY

NCT03129126 - The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis | Biotech Hunter | Biotech Hunter